Clinical Trial News and Research

RSS

nSpire Health sales increase 3% to $27.6M for 2011

nSpire Health, LLC, a leading provider of respiratory diagnostic devices and clinical trial services, issued audited results for 2010 today. Sales of $27.6M are up 3% year over year. The Company reported a $3.6M improvement in EBIT when compared to 2009 and its highest profit since the founding of the company in 2006. Cash is up $2.4M and debt reduced to less than $400K.

25 Apr 2011

Maxwell Biotech, Sequella enter license agreement to commercialize SQ109 for TB treatment

Sequella, a clinical-stage pharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, and Maxwell Biotech Venture Fund announced their agreement to complete the clinical development and commercialize SQ109 for treatment of tuberculosis in the Russian Federation and neighboring Commonwealth of Independent States countries, including Armenia, Azerbaijan, Belorussia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, and Ukraine.

25 Apr 2011

Study shows neutralizing antibodies against GM-CSF can halt MS development

The neutralization of the cytokine GM-CSF could halt the development of multiple sclerosis. This was demonstrated by the research team of the immunologist Burkhard Becher at the University of Zurich in an animal model.

25 Apr 2011

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Idera Pharmaceuticals, Inc. today announced that it has chosen to delay initiating its planned Phase 2 clinical trial of IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study of IMO-2125 in rodents. The Phase 2 clinical trial involves the evaluation of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 hepatitis C virus (HCV) patients.

22 Apr 2011

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Daiichi Sankyo Company, Limited, announced today that the company has received its first marketing approval for LIXIANA 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan.

22 Apr 2011

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

22 Apr 2011

Velos and Comaiba collaborate to provide healthcare risk and compliance management solutions

Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions, today announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management.

22 Apr 2011

Acupuncture offers long-lasting relief for patients after prostate cancer treatment

Acupuncture provides long-lasting relief to hot flashes, heart palpitations and anxiety due to side effects of the hormone given to counteract testosterone, the hormone that induces prostate cancer, according to a study published in the April issue of the International Journal of Radiation Oncology-Biology-Physics, an official journal of the American Society for Radiation Oncology.

22 Apr 2011

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic stress disorder.

22 Apr 2011

Endologix total revenue increases 28% to $18.5 million for first quarter 2011

Endologix, Inc., developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three months ended March 31, 2011.

22 Apr 2011

Convergence initiates CNV2197944 Phase I study in chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun.

22 Apr 2011

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, embolization particles will show the most significant growth, both in procedure volume and in revenue, among all devices in the transcatheter embolization and occlusion (TEO) market. Radioembolization is expected to grow from $50 million in sales in 2011 to $128 million in 2015, while drug-eluting beads will grow from $11 million to $28 million over the same period.

21 Apr 2011

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Six-and-a-half weeks after receiving the first hand transplant in the western United States, Emily Fennell is becoming so accustomed to her new right hand that she barely remembers when she didn't have one.

21 Apr 2011

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Merck and Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today the initiation of a Phase III clinical program to evaluate the safety and immunogenicity of an investigational pediatric hexavalent combination vaccine.

21 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

UnitedHealth Group's consolidated first quarter 2011 revenues increased 10% year-over-year

UnitedHealth Group today reported first quarter results, highlighted by accelerated revenue growth from both its UnitedHealthcare and Optum businesses.

21 Apr 2011

Alexion first quarter non-GAAP net income increases to $56.3 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three months ended March 31, 2011. Alexion Pharmaceuticals, Inc. reported net product sales of Soliris® (eculizumab) of $166.1 million, reflecting steady additions of new patients, compared to $117.6 million for the same period in 2010.

21 Apr 2011

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, today reported positive clinical data from a Phase 2 trial evaluating JX-594 for liver cancer which was conducted in South Korea.

21 Apr 2011

Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability

The Stanford University School of Medicine and SanBio Inc. today announced the initiation of a Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic cell therapy product, SB623, on patients suffering from stable deficits resulting from previous stroke injuries.

21 Apr 2011

KellBenx secures $2.5 million from initial funding round

KellBenx, a biotechnology company focused on the development of non-invasive prenatal diagnosis (NIPD) of genetic and inherited disorders, announced today that it has secured an initial funding round of $2.5 million from four investors – three biotechnology venture capital groups and one angel investor. The round will finance a clinical trial and laboratory testing of a new, minimally invasive blood test designed to identify risks to pregnancy ranging from pre-term birth to genetic conditions.

21 Apr 2011

Clinical Trial News and Research

nSpire Health sales increase 3% to $27.6M for 2011

Maxwell Biotech, Sequella enter license agreement to commercialize SQ109 for TB treatment

Study shows neutralizing antibodies against GM-CSF can halt MS development

Idera announces delay in commencement of IMO-2125 Phase 2 clinical trial in treatment-naive HCV patients

Daiichi Sankyo's LIXIANA receives Japanese marketing approval

Atrasentan provides no additional benefits in phase III clinical trial for advanced prostate cancer

Velos and Comaiba collaborate to provide healthcare risk and compliance management solutions

Acupuncture offers long-lasting relief for patients after prostate cancer treatment

Marinus initiates ganaxolone Phase 2 trial in posttraumatic stress disorder

Endologix total revenue increases 28% to $18.5 million for first quarter 2011

Convergence initiates CNV2197944 Phase I study in chronic pain

MRG: Radioembolization is expected to grow from $50M in sales in 2011 to $128M in 2015

First UCLA patient with hand transplant doing well at six-and-a-half weeks

Merck and Sanofi Pasteur commence Phase III trial of pediatric hexavalent combination vaccine

Repligen anticipates 30% increase in total revenues for 2011

UnitedHealth Group's consolidated first quarter 2011 revenues increased 10% year-over-year

Alexion first quarter non-GAAP net income increases to $56.3 million

Jennerex and Green Cross report positive phase 2 JX-594 clinical trial for liver cancer

Stanford and SanBio initiate SB623 Phase 1/2a clinical trial for stroke disability

KellBenx secures $2.5 million from initial funding round

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News